BASF Environmental Catalyst and Metal Solutions abre caminho para novo investimento em hidrogênio verde em Budenheim, Alemanha

  • Nova instalação produzirá componentes de eletrólise e célula de combustível em apoio à transição energética global
  • A produção deve ter início em meados de 2025
  • Investimento conjunto com outros parceiros

BUDENHEIM, Alemanha, July 11, 2024 (GLOBE NEWSWIRE) — A BASF Environmental Catalyst and Metal Solutions (ECMS) deu início à construção da sua primeira instalação de produção de última geração para componentes de hidrogênio verde e células de combustível em Budenheim, Alemanha, perto de Frankfurt. Os produtos produzidos neste local incluirão membranas revestidas com catalisador de baixo teor de irídio (CCMs) recém-desenvolvidas, uma parte funcional fundamental para a eletrólise da água da membrana de troca de prótons (PEM). Isso complementará os conjuntos de eletrodos de membrana (MEAs) Celtec® para células a combustível de alta temperatura, que também serão produzidos na instalação. Os MEAs são componentes essenciais das células de combustível que permitem que o hidrogênio, juntamente com o oxigênio do ar, seja convertido eficientemente em eletricidade.

A unidade de hidrogênio da ECMS tem operações em todo o mundo, com atividades na Europa, América do Norte e Ásia. Com o rápido desenvolvimento do ecossistema de energia renovável, a produção de hidrogênio verde a partir da eletrólise da água se tornará um pilar essencial em apoio à transição energética global. A nova instalação permitirá o lançamento comercial de CCMs recém-desenvolvidos para eletrolisadores PEM com capacidade de vários gigawatts para atender ao mercado global. Esse investimento permite que os ECMS expandam suas capacidades em metais preciosos, catalisadores e reciclagem, posicionando-se como um provedor de soluções integradas, de ciclo total e completo em uma variedade de linhas de produtos no espaço de hidrogênio verde.

“Esta nova unidade em Budenheim cumpre uma parte fundamental da nossa estratégia global de hidrogênio”, disse Tim Ingle, Vice-Presidente Sênior de Serviços e Reciclagem de Metais Preciosos para ECMS. “Como líder global em serviços de metais preciosos e reciclagem de catalisadores, o investimento solidifica nosso apoio à crescente economia de hidrogênio com soluções circulares que aprimoram o desempenho e reduzem os custos dos eletrolisadores PEM e das células de combustível.”

“Nossos novos produtos progrediram com sucesso da P&D para a escala piloto. A produção em Budenheim significa um marco importante para a introdução no mercado desses produtos e nos coloca em uma forte posição para que possamos aproveitar essa grande oportunidade para os negócios”, disse Saeed Alerasool, Vice-Presidente Sênior de P&D e Aplicação para ECMS.

A inauguração do site em Budenheim está prevista para meados de 2025. A instalação em um local industrial, está situada no centro da Europa, dentro da área metropolitana de Rhein-Main. O projeto está sendo desenvolvido com a Trigona Fuel Cell Components GmbH e a Grundstücksverwaltung Rheinufer GmbH & Co. KG.

Sobre a BASF Environmental Catalyst and Metal Solutions

Aproveitando sua profunda experiência como líder global em catálise e metais preciosos, a BASF Environmental Catalyst and Metal Solutions (ECMS) atende clientes em muitos setores, incluindo automotivo, aeroespacial, qualidade do ar interno, semicondutores e economia de hidrogênio, e fornece serviços de ciclo completo com sua oferta de comércio e reciclagem de metais preciosos. Com foco nas soluções circulares e sustentabilidade, a ECMS está comprometida em ajudar nossos clientes a criar um mundo mais limpo e sustentável. O nosso novo objetivo de proteger os elementos da vida nos inspira a criar soluções sempre novas. A ECMS opera em 16 países, conta com mais de 4.500 funcionários e 21 locais de produção.

Contato de Relações com a Mídia:
Betsy Arnone
+1 973-519-9808
Email: betsy.arnone@basf-catalystsmetals.com
Contato Adicional:
Katarzyna Postawa
+48 882001062
Email: katarzyna.postawa@basf-catalystsmetals.com
BASF ECMS
33 S. Wood Ave
Iselin, NJ 08830
www.basf.com/ecms

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/8c267139-bb57-4ebf-9a9c-411bbbfa7787

GlobeNewswire Distribution ID 9176660

BASF Environmental Catalyst and Metal Solutions inaugure un nouvel investissement dans l’hydrogène vert à Budenheim, en Allemagne

  • La nouvelle installation produira des composants pour l’électrolyse et les piles à combustible afin de soutenir la transition énergétique mondiale
  • La production devrait commencer à l’été 2025
  • Investissement conjoint avec d’autres partenaires

BUDENHEIM, Allemagne, 11 juill. 2024 (GLOBE NEWSWIRE) — BASF Environmental Catalyst and Metal Solutions (ECMS) a entamé la construction de sa première installation de production de pointe pour l’hydrogène vert et les composants de piles à combustible à Budenheim, en Allemagne, près de Francfort. Les produits fabriqués sur ce site incluront des membranes revêtues de catalyseur (CCM) à faible teneur en iridium récemment développées, un élément fonctionnel clé pour l’électrolyse de l’eau à membrane échangeuse de protons (PEM). Ces membranes viendront compléter les assemblages membrane-électrode (AME) Celtec® pour les piles à combustible à haute température, qui seront également produites sur le site. Les AME sont des composants essentiels des piles à combustible qui permettent de convertir efficacement l’hydrogène associé à l’oxygène de l’air en électricité.

La division hydrogène de la société ECMS est présente dans le monde entier, et exerce ses activités en Europe, en Amérique du Nord et en Asie. Avec le développement rapide de l’écosystème des énergies renouvelables, la production d’hydrogène vert à partir de l’électrolyse de l’eau deviendra un pilier essentiel pour soutenir la transition énergétique mondiale. La nouvelle installation permettra le lancement commercial des CCM fraîchement développées pour les électrolyseurs PEM d’une capacité de plusieurs gigawatts afin de desservir le marché mondial. Cet investissement permet à ECMS d’étendre ses compétences dans le domaine des métaux précieux, des catalyseurs et du recyclage, et de se positionner comme un fournisseur de solutions intégrées, en boucle complète et de bout en bout, pour toute une série de gammes de produits dans le domaine de l’hydrogène vert.

« Ce nouveau site à Budenheim est un élément clé de notre stratégie mondiale en matière d’hydrogène », a déclaré Tim Ingle, vice-président principal des services et du recyclage des métaux précieux pour ECMS. « En tant que leader mondial dans le domaine des services liés aux métaux précieux et du recyclage des catalyseurs, cet investissement renforce notre contribution à la croissance de l’économie de l’hydrogène grâce à des solutions circulaires qui améliorent les performances et réduisent les coûts des électrolyseurs PEM et des piles à combustible ».

« Nos nouveaux produits ont évolué avec succès du stade de la R&D à celui de projet pilote. La production à Budenheim représente une étape importante pour l’introduction de ces produits sur le marché et nous place en bonne position pour tirer parti de cette formidable opportunité commerciale », a précisé Saeed Alerasool, vice-président principal chargé de la R&D et des applications pour ECMS.

L’ouverture du site de Budenheim est prévue pour l’été 2025. L’installation, dans les locaux d’un site industriel, est située au centre de l’Europe, dans la région métropolitaine Rhin-Main. Le projet est développé avec Trigona Fuel Cell Components GmbH et Grundstücksverwaltung Rheinufer GmbH & Co. KG.

À propos de BASF Environmental Catalyst and Metal Solutions

Exploitant sa grande expertise en tant que leader mondial de la catalyse et des métaux précieux, BASF Environmental Catalyst and Metal Solutions (ECMS) est au service de clients dans de nombreux secteurs, notamment l’automobile, l’aérospatiale, la qualité de l’air intérieur, les semi-conducteurs et l’économie de l’hydrogène, et fournit des services en boucle complète grâce à son offre de négoce et de recyclage des métaux précieux. En mettant l’accent sur les solutions circulaires et la durabilité, ECMS s’engage à assister ses clients dans la création d’un monde plus propre et plus durable. Protéger les éléments de la vie est notre objectif et cela nous inspire dans la recherche de solutions toujours nouvelles. ECMS est présent dans 16 pays et compte plus de 4 500 employés sur 21 sites de production.

Contact relations avec les médias :
Betsy Arnone
+1 973-519-9808
E-mail : betsy.arnone@basf-catalystsmetals.com
Contact supplémentaire :
Katarzyna Postawa
+48 882001062
E-mail : katarzyna.postawa@basf-catalystsmetals.com
BASF ECMS
33 S. Wood Ave
Iselin, NJ 08830
www.basf.com/ecms

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/8c267139-bb57-4ebf-9a9c-411bbbfa7787

GlobeNewswire Distribution ID 9176660

BASF Environmental Catalyst and Metal Solutions breaks ground on new green hydrogen investment in Budenheim, Germany

Groundbreaking of new green hydrogen production facility in Budenheim, Germany
Pictured left to right: Dr. Günter Krummel, Gesellschafter Trigona FCC; André Semann, CFO Budenheim; Meaghan McGuire, Head of Strategic Marketing, Hydrogen, BASF ECMS; Tim Ingle, SVP Precious Metal Services and Recycling, BASF ECMS; Saeed Alerasool, SVP R&D and Application, BASF ECMS; Daniel Malko, Head of Operations, Hydrogen, BASF ECMS; Armin Arnaut, Senior Manager Bau- & Facility management Geschwister Oetker Beteiligungen KG; Jason Cox, Global Head of Hydrogen Business, BASF ECMS; Katarzyna Postawa, EMEA Communications Manager, BASF ECMS; Jurica Vidaković, Geschäftsführer Trigona FCC; Thomas Reinel, Geschäftsführer ries+ries Architekten Ingenieure GmbH; Christian Meyer, Bauingenieur Budenheim
  • New facility will produce electrolysis and fuel cell components to support the global energy transition
  • Production is planned to commence in the summer of 2025
  • Joint investment with other partners

BUDENHEIM, Germany, July 10, 2024 (GLOBE NEWSWIRE) — BASF Environmental Catalyst and Metal Solutions (ECMS) commenced construction of its first state-of-the-art production facility for green hydrogen and fuel cell components in Budenheim, Germany, near Frankfurt. The products produced at this site will include newly developed low-iridium-loaded catalyst coated membranes (CCMs), a key functional part for proton exchange membrane (PEM) water electrolysis. This will complement the Celtec® membrane electrode assemblies (MEAs) for high-temperature fuel cells, which will also be produced at the facility. MEAs are critical components in fuel cells that enable hydrogen together with oxygen from the air to be converted efficiently into electricity.

The ECMS hydrogen business operates globally, with activities in Europe, North America and Asia. As the renewable energy ecosystem develops rapidly, the production of green hydrogen from water electrolysis will become a crucial pillar in supporting the global energy transition. The new facility will enable the commercial launch of newly developed CCMs for PEM electrolyzers with multi-gigawatt capacity to serve the global market. This investment allows ECMS to expand its capabilities in precious metals, catalysts and recycling, positioning itself as an integrated, full-loop, end-to-end solution provider across a range of product lines in the green hydrogen space.

“This new site in Budenheim fulfills a key part of our global strategy for hydrogen,” said Tim Ingle, Senior Vice President of Precious Metal Services and Recycling for ECMS. “As a global leader in precious metals services and catalyst recycling, the investment solidifies our support for the growing hydrogen economy with circular solutions that improve performance and reduce costs for PEM electrolyzers and fuel cells.”

“Our new products have progressed successfully from R&D into pilot scale. Production in Budenheim signifies a major milestone for the market introduction of these products and positions us in a strong place to leverage this sizeable business opportunity,” said Saeed Alerasool, Senior Vice President R&D and Application for ECMS.

The opening of the Budenheim site is planned for the summer of 2025. The facility, on the premises of an industrial site, is situated in the center of Europe within the Rhein-Main metropolitan area. The project is being developed with Trigona Fuel Cell Components GmbH and Grundstücksverwaltung Rheinufer GmbH & Co. KG.

About BASF Environmental Catalyst and Metal Solutions

Leveraging its deep expertise as a global leader in catalysis and precious metals, BASF Environmental Catalyst and Metal Solutions (ECMS) serves customers in many industries including automotive, aerospace, indoor air quality, semiconductors, and hydrogen economy, and provides full loop services with its precious metals trading and recycling offering. With a focus on circular solutions and sustainability, ECMS is committed to helping our customers create a cleaner, more sustainable world. Protecting the elements of life is our purpose and this inspires us to ever-new solutions. ECMS operates globally in 16 countries with over 4,500 employees and 21 production sites.

Media Relations contact:
Betsy Arnone
+1 973-519-9808
Email: betsy.arnone@basf-catalystsmetals.com
Additional contact:
Katarzyna Postawa
+48 882001062
Email: katarzyna.postawa@basf-catalystsmetals.com
BASF ECMS
33 S. Wood Ave
Iselin, NJ 08830
www.basf.com/ecms

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8c267139-bb57-4ebf-9a9c-411bbbfa7787

GlobeNewswire Distribution ID 9175995

Discover Innovation and Rewards at CHINT Limitless 2024 Super Brand Season

CHINT Limitless super brand season
CHINT Limitless super brand season

Discover Innovation and Rewards at CHINT Limitless 2024 Super Brand Season

SHANGHAI, July 10, 2024 (GLOBE NEWSWIRE) — CHINT is excited to announce the global launch of its “Limitless 2024 Cool Season” campaign, running from June 1st to July 31st, 2024. This exciting campaign aims to honor electricians, installers, and panel builders worldwide, recognizing their invaluable contributions to the industry.

Campaign Overview

Building on the success of the previous two seasons, the Limitless 2024 campaign will feature a variety of online and offline activities, including new product launches and promotions in the new energy, OEM, and construction sectors. Additionally, the campaign will introduce a Global Point Reward System and the CHINT Electrician Ambassador program alongside community-building activities that foster collaboration and recognition.

Reward System

The Global Point Reward System is a key feature of the Limitless 2024 campaign, allowing electricians and installers to earn points with every CHINT purchase. Participants can easily upload their receipts to the activity page and accumulate points. Additionally, a referral program encourages participants to invite their peers, earning bonus points for each successful referral. This system not only rewards loyalty but also fosters a sense of community and collaboration among industry professionals.

New Product Launches

The Limitless 2024 campaign will spotlight several innovative products. These products are designed to enhance safety and efficiency in electrical installations, offering cutting-edge features that cater to the evolving needs of the industry.

1. NF2 Load Switch: This switch offers reliable performance and enhanced safety, ideal for isolating faulty equipment and main switch applications.

2. NM8N HV Series Molded Case Circuit Breaker: This breaker provides robust protection and zero arcing in high-voltage circuits up to 1150V.

3. NL1 Residual Current Operated Circuit Breaker: This circuit breaker offers enhanced protection against electrical faults without over-current protection, ensuring optimal safety.

Conclusion

CHINT encourages electricians and installers worldwide to join the Limitless 2024 campaign and take advantage of innovative products, rewarding systems, and community-building activities. For more details on the campaign, please contact your local CHINT retail store.

About CHINT

Founded in 1984, CHINT is a global leader in smart energy solutions, operating in over 140 countries with more than 40,000 employees. CHINT is committed to innovation, sustainability, and supporting communities with high-quality products and comprehensive energy solutions.

Media contacts:
Company: Zhejiang CHINT Electrics Co., Ltd.
Website: https://chintglobal.com/
Email: global-sales@chint.com
Tel: +86-400-1177797

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/39591ac7-ab99-4da5-8d70-2da20084bf96

GlobeNewswire Distribution ID 9175742

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real-world setting for hemophilia B in Europe.

HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe hemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1

Following European Commission approval, HEMGENIX® was the first ever therapy to be granted Direct Access in France2, thus enabling the first patients to be treated in Europe outside of the clinical program.

Though effective, current therapies can be time intensive and require regular treatment that can have a substantial impact on a patient’s daily life.3 HEMGENIX® offers a one-time treatment, allowing people living with hemophilia B to produce their own Factor IX, which can lower the risk of bleeding.4

“Only a few decades ago, gene therapy for hemophilia was a distant concept, which has now become reality. Accordingly, the first two patients treated with HEMGENIX® since receiving European approval is a major accomplishment and a testament to the joint commitment of the hemophilia B community, as well as the access and reimbursement authorities, in bringing innovative therapies to patients,” said Dr Lutz Bonacker SVP and General Manager, CSL Behring Commercial Operations Europe. “This milestone has been made possible by the innovative Direct Access scheme adopted in France, allowing patients to benefit from early access to pioneering treatments. We are encouraged to see increasing access to gene therapies in European countries and are fully committed to ensuring that access to potentially life-changing treatment continues.”

HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022. It has also been approved by Health Canada, the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), Switzerland’s Swissmedic and Australia’s Therapeutic Goods Administration (TGA).

The multi-year clinical development of HEMGENIX® was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment.

About Hemophilia B

Hemophilia B is a life-threatening rare disease. People with the condition are particularly vulnerable to bleeds in their joints, muscles, and internal organs, leading to pain, swelling, and joint damage. Current treatments for moderate to severe hemophilia B include life-long prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood-clotting factor.

About HEMGENIX®

HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non-infectious viral vector, called an adeno-associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX-Padua) to the target cells in the liver, generating factor IX proteins that are 5x-8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person’s own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.

About the Pivotal HOPE-B Trial

The pivotal Phase III HOPE-B trial is an ongoing, multinational, open-label, single-arm study to evaluate the safety and efficacy of HEMGENIX®. Fifty-four adult hemophilia B patients classified as having moderately severe to severe hemophilia B and requiring prophylactic factor IX replacement therapy were enrolled in a prospective, six-month or longer observational period during which time they continued to use their current standard of care therapy to establish a baseline Annual Bleeding Rate (ABR). After the six-month lead-in period, patients received a single intravenous administration of HEMGENIX® at the 2×10^13 gc/kg dose. Patients were not excluded from the trial based on pre-existing neutralizing antibodies (NAbs) to AAV5.

A total of 54 patients received a single dose of HEMGENIX® in the pivotal trial, with 52 patients completing at least three years of follow-up. The primary endpoint in the pivotal HOPE-B study was ABR 52 weeks after achievement of stable factor IX expression (months 7 to 18) compared with the six-month lead-in period. For this endpoint, ABR was measured from month seven to month 18 after infusion, ensuring the observation period represented a steady-state factor IX transgene expression. Secondary endpoints included assessment of factor IX activity.

No serious treatment-related adverse reactions were reported. One death resulting from urosepsis and cardiogenic shock in a 77-year-old patient at 65 weeks following dosing was considered unrelated to treatment by investigators and the company sponsor. A serious adverse event of hepatocellular carcinoma was determined to be unrelated to treatment with HEMGENIX® by independent molecular tumour characterization and vector integration analysis. No inhibitors to factor IX were reported.

Long-term three-year data presented at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 2024 continue to reinforce the potential long-lasting efficacy and safety of HEMGENIX® and the ongoing benefit of this treatment for people living with hemophilia B.

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.

Media Contacts
Stephanie Fuchs
Mobile: +49 151 584 388 60
Email: Stephanie.Fuchs@cslbehring.com

References


1 European Medicines Agency. First Gene therapy to treat haemophilia B. Available at: https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b. [Accessed May 2024].
2 Republique Française. Légifrance: Article 62 of Law No. 2021-1754. Available at: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000048551003 [Accessed May 2024].
3 Leebeek, F & Miesbach, W. (2021) Gene therapy for haemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. Vol 138, Issue 11. pp923-931.
4 Coppens M et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. The Lancet Haematology 2024; 11(4):E265-E275.

GlobeNewswire Distribution ID 1000969961

Adrian Ridge est nommé directeur général de Nikkiso Clean Energy & Industrial Gases Group

TEMECULA, Californie, 02 juill. 2024 (GLOBE NEWSWIRE) — À compter du 1er juillet 2024, Adrian Ridge est directeur général de Nikkiso Clean Energy & Industrial Gases Group, qui fait partie de la branche industrielle de Nikkiso Co. Ltd. Ridge succède à Peter Wagner, qui reste engagé au sein du conseil d’administration en tant que président exécutif de Nikkiso CE&IG Group.

En tant que directeur général, Ridge pilotera les performances opérationnelles et financières du Groupe et le préparera à sa croissance future. Dans son rôle de président exécutif, Wagner se concentrera sur la mise en œuvre de la vision et de la stratégie à long terme du Groupe en qualité de conseiller.

« Au nom du conseil d’administration, je souhaite la bienvenue et félicite Adrian pour sa promotion au poste de directeur général », a déclaré Wagner. « C’est un leader confirmé qui s’engage au bon moment pour soutenir la croissance de Nikkiso Clean Energy & Industrial Gases vers de nouveaux sommets. »

« Je n’ai jamais été aussi enthousiasmé par le potentiel d’une entreprise que par celui de Nikkiso », a affirmé Ridge. « Nous disposons de tous les ingrédients nécessaires pour être leader sur tous les marchés que nous desservons dans toutes les régions du monde. Je suis honoré et reconnaissant pour cette opportunité unique. »

À propos d’Adrian Ridge

Ridge a rejoint Nikkiso Clean Energy & Industrial Gases en 2022 en tant que vice-président directeur de la fabrication et des opérations après avoir travaillé près de 30 ans chez le géant manufacturier suédois Atlas Copco où il a occupé plusieurs postes de direction au niveau mondial. Il est titulaire d’un diplôme en génie mécanique et d’un MBA de l’Université de Durham au Royaume-Uni.

Contact média
Lisa Adams
Lisa.adams@nikkisoceig.com
Mobile : +1 405 492-1689

À propos de Nikkiso Clean Energy & Industrial Gases Group

Nikkiso Clean Energy & Industrial Gases Group est un fournisseur leader d’équipements cryogéniques et de technologies et d’applications conçues pour les marchés inhérents à l’énergie propre et aux gaz industriels. Le Groupe emploie plus de 1 600 personnes dans 22 pays sous la direction de Cryogenic Industries, Inc. en Californie du Sud, aux États-Unis, qui est une filiale à 100 % de Nikkiso Co., Ltd. (TSE: 6376).

Une photo accompagnant cette annonce est disponible sur https://www.globenewswire.com/NewsRoom/AttachmentNg/b3496ba9-85d1-4c91-b199-181d30747a25

GlobeNewswire Distribution ID 9172603